On Friday, PDS Biotechnology Corporation (NASDAQ: PDSB) opened lower -8.21% from the last session, before settling in for the closing price of $1.34. Price fluctuations for PDSB have ranged from $1.13 to $6.16 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 20.14% at the time writing. With a float of $42.90 million, this company’s outstanding shares have now reached $44.59 million.
The extent of productivity of a business whose workforce counts for 25 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
PDS Biotechnology Corporation (PDSB) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of PDS Biotechnology Corporation is 3.78%, while institutional ownership is 9.52%. The most recent insider transaction that took place on Feb 28 ’25, was worth 25,000. In this transaction Director of this company bought 15,060 shares at a rate of $1.66, taking the stock ownership to the 61,213 shares. Before that another transaction happened on Feb 28 ’25, when Company’s Director bought 15,061 for $1.66, making the entire transaction worth $25,001. This insider now owns 78,851 shares in total.
PDS Biotechnology Corporation (PDSB) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 20.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 3.39% during the next five years compared to 42.97% growth over the previous five years of trading.
PDS Biotechnology Corporation (NASDAQ: PDSB) Trading Performance Indicators
Check out the current performance indicators for PDS Biotechnology Corporation (PDSB). In the past quarter, the stock posted a quick ratio of 2.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.17, a number that is poised to hit -0.28 in the next quarter and is forecasted to reach -1.22 in one year’s time.
Technical Analysis of PDS Biotechnology Corporation (PDSB)
The latest stats from [PDS Biotechnology Corporation, PDSB] show that its last 5-days average volume of 2.18 million was superior to 0.74 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 15.26%. Additionally, its Average True Range was 0.20.
During the past 100 days, PDS Biotechnology Corporation’s (PDSB) raw stochastic average was set at 4.26%, which indicates a significant decrease from 9.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 126.34% in the past 14 days, which was higher than the 93.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4984, while its 200-day Moving Average is $2.6535. Now, the first resistance to watch is $1.4083. This is followed by the second major resistance level at $1.5867. The third major resistance level sits at $1.6833. If the price goes on to break the first support level at $1.1333, it is likely to go to the next support level at $1.0367. Assuming the price breaks the second support level, the third support level stands at $0.8583.
PDS Biotechnology Corporation (NASDAQ: PDSB) Key Stats
There are currently 38,193K shares outstanding in the company with a market cap of 54.85 million. Presently, the company’s annual sales total 0 K according to its annual income of -42,940 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -10,730 K.
